ONCT-534 Earns FDA Fast Track Designa... - Advanced Prostate...

Advanced Prostate Cancer

21,056 members26,262 posts

ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC

Maxone73 profile image
5 Replies

ONCT-534 recruiting

cancernetwork.com/view/onct...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
5 Replies
kainasar profile image
kainasar

Thanks. Their is still hope.

Scout4answers profile image
Scout4answers

According to findings from preclinical studies, the agent has demonstrated activity in prostate cancer models with and without AR mutations.

Does not say what the basis for fast track is. Could it be more than mouse models?

Maxone73 profile image
Maxone73 in reply to Scout4answers

it's for investigational drugs development, I thought it would happen after an incredibly promising start of phase 1, but it seems that the potential and the fact that it would be a lifesaver can be enough

from what I read they will sun a phase 1/2 instead of two separate phases

Maxone73 profile image
Maxone73 in reply to Scout4answers

ah here you go: onclive.com/view/fda-allows...

they were already in phase 1/2 in august

j-o-h-n profile image
j-o-h-n

Good Luck, Good Health and Good Humor.

j-o-h-n Monday 10/30/2023 7:45 PM DST

My work of art............Little bastards having fun with my body.

You may also like...

Another Lu-177 solution gets fast tracked: Lu-177-DGUL, secures 'GIFT' designation

from its “Global Innovative Products on Fast Track” (GIFT) program, signifying a significant...

FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

the FDA. The article has the basic results of the ARASENS trial. https://www.onclive.com/view/fda

ONCT-534 some trial data soon?

The company developing ONCT-534 will take part at Oppenheimer 34th Annual Healthcare Life Sciences

Marijuana use may be associated with reduced prevalence of prostate cancer - cross sectional study

https://doi.org/10.1200/JCO.2024.42.4_suppl. The study seems quite small “Results: Prevalence of

Help with choosing treatment pathway

Diagnosed March 2020 with Stage 4 high volume metastatic prostate cancer. Gleason score 9 (4+5),...